Solo fliers are getting hit with higher fares — here's how airlines are getting away with it
Reportedly, Delta is one of a few airlines that are now charging extra for single flight tickets.
According to View From The Wing, technically some of the airlines disclose in their fare fules that if a customer purchases an individual ticket — even if it's one of their cheapest fare options — that they'll be charged more unless they have someone accompanying them on the flight.
3 Reportedly, Delta is one of a few airlines that are now charging extra for single flight tickets.
miglagoa – stock.adobe.com
The team at Thrifty Traveler did some digging and pointed out that this price hike for solo tickets isn't for every airlines' flight route and it's unclear how long this increased fare will go on for.
And it seems that Delta isn't the only airline being greedy. United and American airlines are supposedly also taking this approach with price gouging.
Thrifty Traveler found that a single one-way standard economy United ticket traveling from Chicago-O'Hare to Peoria costs $269.
But if you tack on a few more people to the reservation, that almost $300 ticket fare drops to less than $200 per person.
3 The airlines aren't even being sneaky with their price gouging tactics.
Getty Images
United isn't trying to be sneaky about it either — it's written in the fare fules for this ticket: 'Must be accompanied on all sectors in same compartment by at least 1 adult 15 or older.'
It's easy for solo passengers to not even realize this price difference — so their best bet, if they're able to, is to shop around different airlines to get the best bang for their buck.
3 Those looking to travel solo should shop around for the best airfare prices.
Goffkein – stock.adobe.com
The good news is that overall, flight prices for summer travel are down 7% year-over-year, according to Eric Rosen, the director of travel content at The Points Guy and a Kayak report.
'It's quite significant for prices to drop that much,' he told The Post.
And international airfare is seeing an even greater price decrease, with flight tickets to hot spots like Sydney, Hong Kong and Berlin — down by 23%, 16% and 13%.
While you're looking for the best prices on airfare, also take a peek at off-the-beaten-path routes that airlines are adding to their network.
'United is putting a Greenland — which is in Denmark — flight into service on June 14, which could be interesting for folks who want to take an adventure-type trip,' Rosen suggested.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
an hour ago
- Fast Company
U.S. and European Union trade deal could cost the pharma industry up to $19 billion
The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said on Monday. The added costs could raise prices for consumers unless pharmaceutical companies take action to mitigate the impact of the tariffs, one of the analysts said. Pharmaceuticals had historically been exempt from duties. Medicines are the largest European exports to the United States by value and the EU accounts for about 60% of all pharmaceutical imports to the U.S. On Sunday, European officials said that a bilateral trade deal for an across-the-board 15% tariff included pharmaceuticals, except for some generic drugs, which would be subject to no tariffs. The U.S. has been conducting a national security investigation into the pharmaceutical sector and the industry has been bracing for separate sectoral tariffs. President Donald Trump said earlier this month, before negotiating the bilateral deal, that pharmaceutical tariffs could be as high as 200%. Some Wall Street analysts said that they do not expect additional tariffs on the EU as a result of the investigation, but others cautioned that the deal was not yet signed and that several questions remained unanswered. UBS analyst Matthew Weston said that he expects details of the trade deal to include protective measures for EU pharma exports from the U.S. investigation, especially since such measures are being discussed in negotiations with the United Kingdom and Switzerland. ING analyst Diederik Stadig also said that while tariffs on top of the 15% were not expected, even after the conclusion of the national security investigations, nothing is completely clear 'until a trade deal is inked.' Stadig estimates that these levies could add $13 billion to industry expenses without any mitigation strategies, and some of that could be ultimately borne by the consumer. Bernstein analyst Courtney Breen puts the additional expenses at $19 billion for the industry, but she notes that companies might be able to absorb some of the costs with the measures they have been implementing—such as stockpiling of drug products and new deals with contract researchers. Earlier this month, Sanofi said it will sell a manufacturing facility in New Jersey to Thermo Fisher, where the French drugmaker's therapies will continue to be manufactured. Roche's CEO Thomas Schinecker said last week that the company was increasing its U.S. inventories to avoid any immediate disruption from tariffs. UBS' Weston said that it was not immediately clear which generic drugs were exempted from duties under the deal, but any impact for generic drugmaker Sandoz for this year should mostly be manageable. Shares in pharmaceutical companies Sanofi, Roche and Sandoz Group all closed up between 0.5% and 1% on Monday.
Yahoo
3 hours ago
- Yahoo
EU-US trade deal could add up to $19 billion in pharma industry costs, analysts say
By Bhanvi Satija (Reuters) -The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said on Monday. The added costs could raise prices for consumers unless pharmaceutical companies take action to mitigate the impact of the tariffs, one of the analysts said. Pharmaceuticals had historically been exempt from duties. Medicines are the largest European exports to the United States by value and the EU accounts for about 60% of all pharmaceutical imports to the U.S. On Sunday, European officials said that a bilateral trade deal for an across-the-board 15% tariff included pharmaceuticals, except for some generic drugs, which would be subject to no tariffs. The U.S. has been conducting a national security investigation into the pharmaceutical sector and the industry has been bracing for separate sectoral tariffs. President Donald Trump said earlier this month, before negotiating the bilateral deal, that pharmaceutical tariffs could be as high as 200%. Some Wall Street analysts said that they do not expect additional tariffs on the EU as a result of the investigation, but others cautioned that the deal was not yet signed and that several questions remained unanswered. UBS analyst Matthew Weston said that he expects details of the trade deal to include protective measures for EU pharma exports from the U.S. investigation, especially since such measures are being discussed in negotiations with the United Kingdom and Switzerland. ING analyst Diederik Stadig also said that while tariffs on top of the 15% were not expected, even after the conclusion of the national security investigations, nothing is completely clear "until a trade deal is inked." Stadig estimates that these levies could add $13 billion to industry expenses without any mitigation strategies, and some of that could be ultimately borne by the consumer. Bernstein analyst Courtney Breen puts the additional expenses at $19 billion for the industry, but she notes that companies might be able to absorb some of the costs with the measures they have been implementing — such as stockpiling of drug products and new deals with contract researchers. Earlier this month, Sanofi said it will sell a manufacturing facility in New Jersey to Thermo Fisher, where the French drugmaker's therapies will continue to be manufactured. Roche's CEO Thomas Schinecker said last week that the company was increasing its U.S. inventories to avoid any immediate disruption from tariffs. UBS' Weston said that it was not immediately clear which generic drugs were exempted from duties under the deal, but any impact for generic drugmaker Sandoz for this year should mostly be manageable. Shares in pharmaceutical companies Sanofi, Roche and Sandoz Group all closed up between 0.5% and 1% on Monday. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Fox News
3 hours ago
- Fox News
CNBC's Jim Cramer drops F-bomb live on air while marveling over Trump's ‘great economy'
CNBC host Jim Cramer's excitement about President Donald Trump's latest trade deal got the better of him on Monday. Cramer blurted out "What the f---!" during a segment of CNBC's "Squawk on The Street" after seeing a graphic detailing the United States' recent trade deals with various countries, including a major trade deal made with the European Union on Sunday. "Our biggest problem is we have so much growth that the Fed won't cut. What the f---!" the co-host exclaimed, regretting it as soon as he said it. "Oh my God! I'm so sorry," Cramer said. "I'm so sorry. I take it right back. I take it right back. That was bad." His co-hosts David Faber and Carl Quintanilla reassured their colleague it wasn't a big deal. "It's OK. It's OK. It's OK!," Faber told Cramer as he kept apologizing. "We're in the moment. It's just the way we talk." "Real people doing live TV," Quintanilla added. Cramer continued: "I'm done. I think I'm out of here." "No, you're fine," Faber replied, laughing. "You're absolutely fine. You want me to say one?" Cramer said, "No, I just feel like, enough with the rate cut and the economy's booming." The anchor also apologized on X following the appearance. He wrote, "I apologize to all viewers. I was too effusive in making my point about the great economy we have.." Trump averted a trade war and notched another win on Sunday. The president and European Commission President Ursula von der Leyen announced a trade deal between the U.S. and the European Union that set a 15-percent tariff on most EU goods imported into the U.S. Von der Leyen said Europe will also purchase $150 billion worth of U.S. energy as part of the deal, in addition to making $600 billion in other investments. The agreement comes days after Trump secured a $550 billion trade deal with Japan. "We just completed a massive Deal with Japan, perhaps the largest Deal ever made," Trump wrote on Truth Social. "Japan will invest, at my direction, $550 Billion Dollars into the United States, which will receive 90% of the Profits. This Deal will create Hundreds of Thousands of Jobs — There has never been anything like it." Some prominent critics of the president have admitted that they were wrong about the damage Trump's tariffs would do to the economy. Most recently, HBO host Bill Maher admitted on his "Club Random" podcast that his predictions were incorrect. "Just to take an example, tariffs. Now I remember that I, along with probably most people, was saying at the beginning, 'Oh, you know, by the 4th of July… the economy was going to be tanked by then,' and I was kind of like, 'Well, that seems right to me,'" he told guest, liberal pundit Brian Tyler Cohen. "But, that didn't happen," Maher said. "It could happen tomorrow. I'm just saying, that's reality, so let's work first from the reality of that, not from 'I just hate Donald Trump,' because that's boring and doesn't get us anywhere and leads you to dishonesty."
